Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 134.78 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 16.62 | |||||
| Beneish M-Score | -3.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 46.2 | |||||
| 3-Year EBITDA Growth Rate | 39.2 | |||||
| 3-Year EPS without NRI Growth Rate | -6.1 | |||||
| 3-Year FCF Growth Rate | 8.7 | |||||
| 3-Year Book Growth Rate | 30.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 43.45 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 17.88 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.09 | |||||
| 9-Day RSI | 53.85 | |||||
| 14-Day RSI | 53.73 | |||||
| 6-1 Month Momentum % | 47.65 | |||||
| 12-1 Month Momentum % | 53.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.11 | |||||
| Quick Ratio | 4.92 | |||||
| Cash Ratio | 4.2 | |||||
| Days Inventory | 95.77 | |||||
| Days Sales Outstanding | 43.99 | |||||
| Days Payable | 56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -5.37 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.32 | |||||
| Operating Margin % | 37.78 | |||||
| Net Margin % | 31.01 | |||||
| FCF Margin % | 48.13 | |||||
| ROE % | 27.81 | |||||
| ROA % | 23.73 | |||||
| ROIC % | 52.33 | |||||
| 3-Year ROIIC % | -3.64 | |||||
| ROC (Joel Greenblatt) % | 1452.29 | |||||
| ROCE % | 33.49 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.58 | |||||
| Forward PE Ratio | 14.55 | |||||
| PE Ratio without NRI | 18.54 | |||||
| Shiller PE Ratio | 86.52 | |||||
| Price-to-Owner-Earnings | 16.17 | |||||
| PS Ratio | 5.8 | |||||
| PB Ratio | 3.96 | |||||
| Price-to-Tangible-Book | 5.28 | |||||
| Price-to-Free-Cash-Flow | 12.05 | |||||
| Price-to-Operating-Cash-Flow | 11.89 | |||||
| EV-to-EBIT | 12.5 | |||||
| EV-to-Forward-EBIT | 7.72 | |||||
| EV-to-EBITDA | 10.29 | |||||
| EV-to-Revenue | 4.72 | |||||
| EV-to-Forward-Revenue | 3.74 | |||||
| EV-to-FCF | 9.81 | |||||
| Price-to-Projected-FCF | 2.21 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.74 | |||||
| Price-to-Graham-Number | 2.08 | |||||
| Price-to-Net-Current-Asset-Value | 6.11 | |||||
| Price-to-Net-Cash | 7.88 | |||||
| Earnings Yield (Greenblatt) % | 8 | |||||
| FCF Yield % | 8.48 | |||||
| Forward Rate of Return (Yacktman) % | 23.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 421.971 | ||
| EPS (TTM) (€) | 1.081 | ||
| Beta | 0.1 | ||
| Volatility % | 32.44 | ||
| 14-Day RSI | 53.73 | ||
| 14-Day ATR (€) | 0.768359 | ||
| 20-Day SMA (€) | 20.6985 | ||
| 12-1 Month Momentum % | 53.68 | ||
| 52-Week Range (€) | 12.185 - 23.21 | ||
| Shares Outstanding (Mil) | 119.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Catalyst Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Catalyst Pharmaceuticals Inc Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc(STU:CN2)'s stock price today?
The current price of STU:CN2 is €21.40. The 52 week high of STU:CN2 is €23.21 and 52 week low is €12.19.
When is next earnings date of Catalyst Pharmaceuticals Inc(STU:CN2)?
The next earnings date of Catalyst Pharmaceuticals Inc(STU:CN2) is 2025-02-28 Est..
Does Catalyst Pharmaceuticals Inc(STU:CN2) pay dividends? If so, how much?
Catalyst Pharmaceuticals Inc(STU:CN2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers